Tilray Brands is strategically positioned for expansion into the U.S. market after federal actions reclassified cannabis from Schedule I to Schedule III. CEO Irwin Simon highlights the company's global medical cannabis expertise as a key advantage. The company anticipates accelerated clinical research, broader patient access, and the development of standardized medical cannabis frameworks, marking a pivotal moment for the industry.

The Philadelphia Semiconductor Index has achieved an unprecedented 16-day winning streak, driven by strong performances from giants like Nvidia, Broadcom, Micron, and AMD. This remarkable surge, fueled by the accelerating artificial intelligence supercycle and robust earnings from key industry players like TSMC, signals a bullish trend in the semiconductor market. All eyes are now on Intel's upcoming earnings report to potentially further solidify this upward momentum.

Banner Corporation reported a significant increase in net profit for Q1 2026, reaching $1.60 per diluted share, up from $1.30 in Q1 2025. Core earnings also saw a 13% rise, driven by resilient core deposits, effective expense management, and a robust net interest margin. The company's loan portfolio experienced modest growth, despite substantial commercial real estate payoffs. Banner also increased its quarterly dividend and received notable industry recognitions, positioning itself for continued growth and capital deployment in the coming year.

Novo Nordisk has unveiled promising results from its PIONEER TEENS trial, indicating that oral semaglutide could become the first oral GLP-1 receptor agonist approved for managing type 2 diabetes in adolescents aged 10-17. The study showed significant blood sugar reduction and a favorable safety profile, addressing a critical unmet medical need amidst rising rates of youth-onset type 2 diabetes globally.

Medpace Holdings (MEDP) shares experienced a significant drop on Thursday after the company's first-quarter bookings fell short of analyst expectations. Despite reporting an otherwise strong financial performance and reaffirming its full-year guidance, the contract research organization (CRO) recorded a book-to-bill ratio of 0.88x, missing Street forecasts ranging from 0.98x to 1.04x. This unexpected bookings miss sent MEDP stock to a nine-month low.